[go: up one dir, main page]

WO2007013894A3 - Phospholipid ether analogs for detecting and treating cancer - Google Patents

Phospholipid ether analogs for detecting and treating cancer Download PDF

Info

Publication number
WO2007013894A3
WO2007013894A3 PCT/US2005/047657 US2005047657W WO2007013894A3 WO 2007013894 A3 WO2007013894 A3 WO 2007013894A3 US 2005047657 W US2005047657 W US 2005047657W WO 2007013894 A3 WO2007013894 A3 WO 2007013894A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
detecting
phospholipid ether
ether analogs
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/047657
Other languages
French (fr)
Other versions
WO2007013894A2 (en
WO2007013894A9 (en
Inventor
Jamey Weichert
Marc Longino
Anatoly Pinchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectar Inc
Original Assignee
Cellectar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Inc filed Critical Cellectar Inc
Priority to JP2007548624A priority Critical patent/JP2008545614A/en
Priority to CA002591907A priority patent/CA2591907A1/en
Priority to MX2007007497A priority patent/MX2007007497A/en
Priority to EP05858499A priority patent/EP1833514A2/en
Priority to US11/382,645 priority patent/US7632644B2/en
Publication of WO2007013894A2 publication Critical patent/WO2007013894A2/en
Publication of WO2007013894A9 publication Critical patent/WO2007013894A9/en
Publication of WO2007013894A3 publication Critical patent/WO2007013894A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma,Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs
PCT/US2005/047657 2004-03-02 2005-12-20 Phospholipid ether analogs for detecting and treating cancer Ceased WO2007013894A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007548624A JP2008545614A (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for cancer detection and therapy
CA002591907A CA2591907A1 (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer
MX2007007497A MX2007007497A (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer.
EP05858499A EP1833514A2 (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer
US11/382,645 US7632644B2 (en) 2004-03-02 2006-05-10 Imaging and selective retention of phospholipid ether analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59319004P 2004-12-20 2004-12-20
US60/593,190 2004-12-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006681 Continuation-In-Part WO2005084716A2 (en) 2004-03-02 2005-03-02 Phospholipid analogs for diagnosis and treatment of cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/024259 Continuation-In-Part WO2006014589A2 (en) 2004-03-02 2005-07-08 Virtual colonoscopy with radiolabeled phospholipid ether analogs
US11/382,645 Continuation-In-Part US7632644B2 (en) 2004-03-02 2006-05-10 Imaging and selective retention of phospholipid ether analogs

Publications (3)

Publication Number Publication Date
WO2007013894A2 WO2007013894A2 (en) 2007-02-01
WO2007013894A9 WO2007013894A9 (en) 2007-03-29
WO2007013894A3 true WO2007013894A3 (en) 2007-04-19

Family

ID=37564093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047657 Ceased WO2007013894A2 (en) 2004-03-02 2005-12-20 Phospholipid ether analogs for detecting and treating cancer

Country Status (6)

Country Link
EP (1) EP1833514A2 (en)
JP (1) JP2008545614A (en)
KR (1) KR20080005178A (en)
CA (1) CA2591907A1 (en)
MX (1) MX2007007497A (en)
WO (1) WO2007013894A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440257T3 (en) * 2004-03-02 2014-01-28 Cellectar, Inc. Phospholipid analog for in vivo diagnosis of cancers
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
JP2008508909A (en) * 2004-07-08 2008-03-27 セレクター，リミティド ライアビリティ カンパニー Virtual colonoscopy using radiolabeled phospholipid ether analogues
ES2549459T3 (en) * 2009-05-11 2015-10-28 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions and methods of use
EP3708192B1 (en) 2009-06-12 2023-08-02 Cellectar, Inc. Ether phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
RU2012114146A (en) * 2009-09-11 2013-10-20 Селлектар, Инк. NONRADIOACTIVE PHOSPHOLIPID COMPOUNDS, COMPOSITIONS AND WAYS OF THEIR APPLICATION
WO2016081203A2 (en) * 2014-11-17 2016-05-26 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
JP6666757B2 (en) * 2016-03-10 2020-03-18 日本メジフィジックス株式会社 Method for quantifying polyoxyethylene nonionic surfactant and method for producing radiopharmaceutical preparation
AU2017286604B2 (en) * 2016-06-14 2023-05-18 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
US10736949B2 (en) 2016-07-18 2020-08-11 Wisconsin Alumni Research Foundation Radiohalogenated agents for in situ immune modulated cancer vaccination
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
KR102396324B1 (en) * 2016-07-25 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 Targeted Radiotherapy Chelates for In Situ Immunomodulatory Cancer Vaccination
KR102758660B1 (en) * 2017-11-10 2025-01-22 위스콘신 얼럼나이 리서어치 화운데이션 Methods of using targeted radiotherapy (TRT) to induce anti-tumor immune responses to immunotherapy
KR20200143688A (en) * 2018-04-10 2020-12-24 셀렉타 바이오사이언시스, 인코퍼레이티드 Split Dosing of Phospholipid Ether Analogs in Cancer Treatment
BR112022006728A2 (en) * 2019-10-10 2022-07-12 Cellectar Biosciences Inc FRACTIONAL DOSAGE OF A PHOSPHOLIPID ETHER ANALOG FOR THE TREATMENT OF CANCER

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US5795561A (en) * 1987-10-23 1998-08-18 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues
WO2005084716A2 (en) * 2004-03-02 2005-09-15 Cellectar, Llc Phospholipid analogs for diagnosis and treatment of cancer
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795561A (en) * 1987-10-23 1998-08-18 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
WO2005084716A2 (en) * 2004-03-02 2005-09-15 Cellectar, Llc Phospholipid analogs for diagnosis and treatment of cancer
WO2006014589A2 (en) * 2004-07-08 2006-02-09 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEICHERT J P ET AL: "Initial Clinical Imaging Results with NM404 in Non-Small Cell Lung Cancer", MOLECULAR IMAGING, MIT PRESS,, US, vol. 3, no. 3, July 2004 (2004-07-01), pages 269 - 270, XP002365141, ISSN: 1535-3508 *

Also Published As

Publication number Publication date
CA2591907A1 (en) 2007-02-01
EP1833514A2 (en) 2007-09-19
MX2007007497A (en) 2008-01-11
KR20080005178A (en) 2008-01-10
JP2008545614A (en) 2008-12-18
WO2007013894A2 (en) 2007-02-01
WO2007013894A9 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2007013894A3 (en) Phospholipid ether analogs for detecting and treating cancer
MX2009012906A (en) Monoclonal antibodies against claudin-18 for treatment of cancer.
Hu et al. miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1
WO2010031551A3 (en) Monoclonal antibodies for treatment of cancer
WO2006052823A3 (en) Biomarkers for prostate cancer metastasis
WO2012047317A3 (en) Tumor specific antibodies and uses therefor
MY141605A (en) Method of treating certain cancers using an estrogen agonist/antagonist
IL180601A0 (en) Methods and compositions for the detection of ovarian cancer
WO2004045521A3 (en) Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
DK1802625T3 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors of CDK2 and angiogenesis and in the treatment of breast, colon, lung and prostate cancer
Koga et al. Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.
MX2009013765A (en) Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof.
BRPI0618920B8 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR THE TREATMENT OF CANCER
IL266563B (en) Heterocyclic compounds used as pdk1 inhibitors
MX2022013783A (en) Copper-containing theragnostic compounds and methods of use.
EP1572100A4 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
PL2211180T3 (en) Use of protein SATB2 as a marker for distinguishing colorectal cancer from other cancers
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
WO2006044826A3 (en) Thiophens and their use as anti-tumor agents
WO2008104805A3 (en) Proteins
GB2490849A (en) Di-asprin derivatives for use in the treatment of colorectal cancer
WO2012092114A3 (en) Oxidosqualene cyclase as a protein target for anticancer therapeutics
WO2011138449A3 (en) Antagonists of sema3e/plexind1 interaction as anti-cancer agents
IL181346A0 (en) Detection of lymph node metastasis from gastric carcinoma
WO2004031774A3 (en) Method for treating or preventing metastasis of colorectal cancers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11382645

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11382645

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2591907

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007497

Country of ref document: MX

Ref document number: 2007548624

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005858499

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077016834

Country of ref document: KR